AU4315689A - Defective hepadnaviruses and producer cell line for vaccines and treatment of liver diseases and disorders - Google Patents

Defective hepadnaviruses and producer cell line for vaccines and treatment of liver diseases and disorders

Info

Publication number
AU4315689A
AU4315689A AU43156/89A AU4315689A AU4315689A AU 4315689 A AU4315689 A AU 4315689A AU 43156/89 A AU43156/89 A AU 43156/89A AU 4315689 A AU4315689 A AU 4315689A AU 4315689 A AU4315689 A AU 4315689A
Authority
AU
Australia
Prior art keywords
dna
hepadnavirus
defective
sequence
dna sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU43156/89A
Other languages
English (en)
Inventor
Arthur Louis Horwich
Jesse William Summers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Fox Chase Cancer Center
Original Assignee
Yale University
Fox Chase Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Fox Chase Cancer Center filed Critical Yale University
Publication of AU4315689A publication Critical patent/AU4315689A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU43156/89A 1988-08-16 1989-08-16 Defective hepadnaviruses and producer cell line for vaccines and treatment of liver diseases and disorders Abandoned AU4315689A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23281188A 1988-08-16 1988-08-16
US232811 1988-08-16

Publications (1)

Publication Number Publication Date
AU4315689A true AU4315689A (en) 1990-03-23

Family

ID=22874695

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43156/89A Abandoned AU4315689A (en) 1988-08-16 1989-08-16 Defective hepadnaviruses and producer cell line for vaccines and treatment of liver diseases and disorders

Country Status (8)

Country Link
EP (1) EP0380656A1 (da)
AU (1) AU4315689A (da)
DK (1) DK93390A (da)
FI (1) FI901876A0 (da)
IE (1) IE892640L (da)
IL (1) IL91335A0 (da)
WO (1) WO1990002176A1 (da)
ZA (1) ZA896246B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
EP0528903B1 (en) * 1990-04-20 1996-09-11 The General Hospital Corporation Methods of preventing viral replication
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US5683873A (en) * 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
DE19517532C2 (de) * 1995-05-12 1999-10-28 Max Planck Gesellschaft HBV-Vektoren und Zellen zu ihrer Bereitstellung
AU4353897A (en) * 1996-09-18 1998-04-14 Board Of Regents, The University Of Texas System Viral defective interfering particles and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861588A (en) * 1985-02-05 1989-08-29 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers

Also Published As

Publication number Publication date
FI901876A0 (fi) 1990-04-12
IE892640L (en) 1990-02-16
WO1990002176A1 (en) 1990-03-08
IL91335A0 (en) 1990-03-19
EP0380656A1 (en) 1990-08-08
DK93390A (da) 1990-06-15
ZA896246B (en) 1990-06-27
DK93390D0 (da) 1990-04-11

Similar Documents

Publication Publication Date Title
Melegari et al. Properties of hepatitis B virus pre-S1 deletion mutants
US5314808A (en) Method for the transformation of cells, particularly eukaryotes by a DNA originating from viruses of hepatitis, more particularly from virus of a B viral hepatitis, and preparations containing the expression products of said DNAs
US5310668A (en) Varicella-zoster virus as a live recombinant vaccine
US7763589B2 (en) Compositions and methods for treating intracellular diseases
JPH02501186A (ja) 異種ウイルス性ペプチド粒子の免疫原
Guo et al. Identification and characterization of avihepadnaviruses isolated from exotic anseriformes maintained in captivity
JPH0587518B2 (da)
FI116851B (fi) Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
US6297048B1 (en) Hepatitis therapeutics
EP0625204B1 (en) Hepatitis therapeutics
JPH0314840B2 (da)
AU656136B2 (en) Methods of preventing viral replication
AU4315689A (en) Defective hepadnaviruses and producer cell line for vaccines and treatment of liver diseases and disorders
Murray Application of recombinant DNA techniques in the development of viral vaccines
CA1337596C (en) Varicella-zoster virus as a live recombinant vaccine
Yu et al. The GDPAL region of the pre-S1 envelope protein is important for morphogenesis of woodchuck hepatitis virus
Murray The Leeuwenhoek Lecture, 1985-A molecular biologist’s view of viral hepatitis
Waring Characterization of hepatitis B virus surface and core antigens using a baculovirus expression system: Potential as carriers for foreign epitopes.
Barrera Molecular determinants of host range and infectivity for hepatitis B virus
CN1050044A (zh) 用作疫苗或用于治疗肝脏疾患的缺陷性肝炎病毒
WATANASEREE et al. COS-7 CELLS BY USING A RECOMBINANT pcDNA I VECTOR KRUAVON BALACHANDRA", KASAMA SUPANARANOND", CHUENCHIT
Wu Characterization of hepatitis B virus (HBV) transcripts in hepatoma cells transfected with cloned HBV DNA with emphasis on the doubly spliced RNA and the X RNA
de Bruin Role for human endonexin II in hepatitis B and hepatitis delta virus infection